New Asthma Inhaler for People on Standard Therapy
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Chinese, between 18 and 75 years old
- You have had asthma for at least 1 year, diagnosed before age 40
- Your asthma is not well-controlled even though you've been on the same medium-dose combination of two inhaled asthma medicines for at least 4 weeks
- Your lung function (FEV1) is below 80% of normal when tested without bronchodilators
- You have not needed steroid pills, emergency care, or hospitalization for asthma in the past 4 weeks
- You are not a current smoker and have not smoked heavily in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study tests a new medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It is for adults who have had asthma for at least a year, have had recent flare-ups needing steroids, and are not taking other biologic treatments.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This study compares two versions of the common asthma rescue inhaler (salbutamol/albuterol) that use different propellants (the gas that pushes the medicine out). The goal is to see if the new propellant works as well as the current one. If you have mild asthma and are on a stable treatment plan, you may be able to join.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.